Neurvati Neurosciences

Our team is proud to work with many global leaders in research and advocacy to help build broader awareness and support for patients and communities impacted by pediatric neurodevelopmental disorders. We look forward to attending Grin Europe’s 6th European GRIN Conference in Barcelona to engage with the GRIN community and share how we are advancing a targeted approach for the potential treatment of GRIN-related neurodevelopmental disorder.  

The team at Neurvati and GRIN Therapeutics, Inc. is proud to announce the initiation of the Astroscape study in patients with #TSC and #FCD type II. This research effort highlights our unwavering commitment to make a profound impact on the lives of individuals and families affected by #rarediseases. We are excited about the strides we are making and remain dedicated to advancing our research for people around the world living with these conditions. 

Neuroimaging techniques have been essential in clinical #neuroscience for decades but have yet to make a significant impact on psychiatric drug development and clinical care. By integrating neuroimaging into precision psychiatry, we can measure drug effects on the brain early to refine dosing and indications and use it in later trials to identify likely responders. This approach has the potential to enhance drug development success, diversify mechanisms, and improve clinical outcomes. In a recent Nature publication, researchers take an industry lens to examine the opportunities and challenges in using #neuroimaging to mitigate risks in drug development and improve clinical efficacy in psychiatric practice, ultimately paving the way for more precise and effective treatments. See here: https://lnkd.in/dUQYTwni

Today our CEO Bruce Leuchter, M.D., will be attending the Bank of America Healthcare Trailblazers Private Company Conference in Boston. As we advance novel therapies targeting a range of neurological and psychiatric disorders, we look forward to engaging with industry leaders and investors across the #biotech and #healthcare industry.

Join Neurvati and GRIN Therapeutics, Inc.'s Chief Medical Officer, Michael Panzara, M.D., MPH, at The Epilepsy Foundation’s 2024 Pipeline Conference as he shares topline results from our global Phase 1b trial evaluating our investigational drug in the potential treatment of GRIN-related neurodevelopmental disorder.  

Synaptic plasticity, or the ability of neurons to form and maintain new connections, is a brain process crucial to learning, memory, mood and sleep. Today, there is a growing focus from #biotech companies and researchers on developing therapies that modulate molecular targets central to synaptic plasticity pathways to treat depression, schizophrenia, PTSD, autism, and neurodegenerative diseases. In this Drug Discovery World article, Anantha Shekhar, M.D., Ph.D., Dean of the University of Pittsburgh School of Medicine, explores synapse structure and function in #neuroscience and how #neuroplasticity can present new opportunities for drug development. Read the full article: https://lnkd.in/gFZX3n_i

Recently a team of neuroscientists from McGill University identified a third group of dopamine neurons that play a critical role in balancing several essential brain functions, including those related to reward, cognition and movement. As we optimize the development of neuroscience therapies, this discovery has the potential to open up new avenues for developing targeted treatments. Understanding this additional dopamine pathway may enhance how we approach conditions such as depression, schizophrenia, and other brain-related disorders. Read the full Technology Networks article to learn more about this pivotal research and its potential impact on the future of #brainhealth: https://lnkd.in/e4E-J-JJ

The team at Neurvati/GRIN Therapeutics, Inc. are proud to announce topline data from our Honeycomb trial for GRIN-related neurodevelopmental disorder. We look forward to continuing to advance this clinical program to meet our goal of bringing a first-in-class treatment to patients as quickly as possible. 

We look forward to Professor Renzo Guerrini, M.D.’s presentation at #EEC2024, where he will present new data from our global Phase 1b Honeycomb trial and provide valuable insights on our progress in bringing hope to patients and their families. 

During the 2024 Alzheimer’s Association International Conference, researchers presented some of the latest studies that show how the field of #Alzheimers disease has advanced and led to new insights about risk, diagnosis and treatment. Rebecca M. Edelmayer, Ph.D., Vice President of Scientific Engagement at Alzheimer's Association®, spoke with NeurologyLive about the groundbreaking research presented at #AAIC24. The discussion includes how blood biomarker tests could revolutionize Alzheimer's disease diagnosis and treatment, as well as the results from a study investigating a glucagon-like peptide-1 (GLP-1) drug for treating mild to moderate Alzheimer's. See the full interview here: https://lnkd.in/e_QEMm7r